Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests.
Antibody assays
Molecular diagnostics
Rapid antigen tests
SARS-CoV-2
Variant of concern
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
23
04
2021
revised:
21
12
2021
accepted:
19
01
2022
pubmed:
28
1
2022
medline:
17
2
2022
entrez:
27
1
2022
Statut:
ppublish
Résumé
Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94-100% of sera from immune competent B.1.1.7 patients 15-26 days after symptom onset. These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate.
Sections du résumé
BACKGROUND
Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance.
OBJECTIVES
To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta).
STUDY DESIGN
Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay.
RESULTS
Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94-100% of sera from immune competent B.1.1.7 patients 15-26 days after symptom onset.
CONCLUSIONS
These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate.
Identifiants
pubmed: 35086043
pii: S1386-6532(22)00016-6
doi: 10.1016/j.jcv.2022.105080
pmc: PMC8770247
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
105080Informations de copyright
Copyright © 2022 Abbott Laboratories. Published by Elsevier B.V. All rights reserved.
Références
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32651238
J Infect Dis. 2021 Apr 8;223(7):1139-1144
pubmed: 33394052
Biotechniques. 2021 Jul;71(1):370-375
pubmed: 34139879
J Clin Virol. 2021 Oct;143:104945
pubmed: 34450558
Res Sq. 2021 Feb 10;:
pubmed: 33594356
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Virus Res. 2014 Dec 19;194:90-9
pubmed: 25451065
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Science. 2020 Jul 31;369(6503):582-587
pubmed: 32513865
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Sci Rep. 2021 Jul 16;11(1):14604
pubmed: 34272449
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Science. 2014 Oct 3;346(6205):56-61
pubmed: 25278604
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
J Clin Pathol. 2022 Jan;75(1):61-64
pubmed: 33144357
J Clin Virol Plus. 2021 Jun;1(1):100013
pubmed: 35262001
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258